Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Opioid Makers Paid Millions to Advocacy Groups

Nate Raymond  |  February 14, 2018

(Reuters)—Five opioid manufacturers, including OxyContin maker Purdue Pharma LP, have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday.1 The report, released by Sen. Claire McCaskill (D-Mo.), says groups who received the…

Filed under:AnalgesicsDrug Updates Tagged with:national opioid addiction epidemicOpioid abuseopioid crisisOpioid manufacturersU.S. Senate

Pfizer’s Biosimilar of Roche’s Rituxan Succeeds in Study

Reuters Staff  |  January 24, 2018

(Reuters)—Pfizer Inc said on Wednesday its biosimilar of Roche’s Rituxan was as effective as the original drug in treating patients with a type of follicular lymphoma, meeting the main goal of a study. The success of Pfizer’s biosimilar comes as Rituxan’s U.S. patent is set to expire later this year. The drug had raked in…

Filed under:Uncategorized Tagged with:Pfizer Inc.RituxanRituxan biosimilarRoche

2017 ACR/ARHP Honors & Awards, Part 2

Richard Quinn  |  January 19, 2018

SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting in San Diego in November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ARHP winners about their individual contributions. In addition, we profile the new class…

Filed under:Meeting ReportsProfessional Topics Tagged with:AC&RACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)Awards

Skin Exam Advised Before Anti-TNF-Alpha Therapy

Rita Buckley  |  January 16, 2018

NEW YORK (Reuters Health)—Using tumor necrosis factor alpha (TNF-alpha) inhibitors for atypical dermatoses may unmask, or perhaps even worsen, cutaneous lymphoma, according to new research. “Our findings suggest that careful skin examination might be required in all patients prescribed anti-TNF-alpha agents, especially those with atypical presentations of benign skin conditions,” says Dr. Joan Guitart of…

Filed under:Drug Updates Tagged with:Anti-TNFAnti-TNF-AlphaCancercutaneous lymphomapsoriasiform dermatitisPsoriasisskinskin disease

Medical Jargon May Cloud Doctor-Patient Communication

Mary Gillis  |  January 2, 2018

(Reuters Health)—When patients misunderstand commonly used medical terms, communication and decision-making may suffer, U.K. researchers say. In a survey of London oral and maxillofacial surgery clinic patients, more than a third of participants did not know the meaning of such terms as benign or lesion and more than half could not define metastasis or lymph…

Filed under:Professional Topics Tagged with:decision-makingpatient communicationpatient educationphysician-patient communication

New Drug Approvals Hit 21-Year High in 2017

Ben Hirschler  |  January 2, 2018

LONDON (Reuters)—U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light—more than double the previous year—while the figure also rose in the European Union. The European Union (EU) recommended 92 new drugs, including generics, up from 81; and China laid out plans to speed up approvals in what…

Filed under:Drug Updates Tagged with:drugdrug approvalsdrug developmentFDAU.S. Food and Drug Administration (FDA)

Vitamin D, Calcium Supplements May Not Lower Fracture Risk

Lisa Rapaport  |  January 1, 2018

(Reuters Health)—Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who don’t use these supplements, a research review suggests. Researchers examined data from 33 previous trials with a total of more than 51,000 people aged 50 or older who were living in the…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)calciumFractureship fractureOsteoporosisosteoporosis treatmentsVitamin D

Rituximab Use Increasing in Treatment of Pediatric Vasculitis

Catherine Kolonko  |  December 20, 2017

According to a large cohort study of pediatric patients, rituximab use is on the rise in the treatment of children diagnosed with vasculitis. Treatment with cyclophosphamide remains common, but it’s beginning to wane. Dialysis and mechanical ventilation also remain common, the study indicates. The retrospective study of hospitalized children in the U.S. included the largest…

Filed under:ConditionsPediatric ConditionsResearch RheumVasculitis Tagged with:AAVAC&RAmerican College of Rheumatology (ACR)antibody-associated vasculitisArthritis Care & ResearchChildrenClinicalcyclophosphamideDiagnosisdrugoutcomepatient carePediatricResearchrheumatologistrheumatologyrituximabstudytherapytreamentVasculitis

Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

Nan Yang, PharmD, & Kurt Oelke, MD, on behalf of the ARHP Practice Committee  |  December 19, 2017

Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Association of Rheumatology Professionals (ARP)bDMARDbenefitsbiologic disease-modifying antirheumatic drugsCardiovascular diseaseClinicalhipkneeoutcomepatient carereplacementResearchRheumatoid arthritisrheumatologistrheumatologyriskstudytherapy

Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

Shivani Garg, MD, Suzana Alex John, MD, & Frehiywot Ayele, MD  |  December 18, 2017

Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…

Filed under:Other Rheumatic ConditionsResearch Rheum Tagged with:Autoimmunecase reportClinicalDiagnosisfellowFellowsFellows ForumHMGCR Ab-related IMNMimmune-mediated necrotizing myopathyinflammatory myopathymorbiditymortalitymuscle weaknessmyalgianecrotizingpatient careResearchrespiratoryrheumatologistrheumatologyStatinstatin-associated myopathy

  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences